Accellix to expand infrastructure with latest $10Mn investment
Category: #business  By Pankaj Singh  Date: 2021-12-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

Accellix to expand infrastructure with latest $10Mn investment

Israel-based biotechnology company, Accellix has announced that it has roped in a $10 million investment from BroadOak Capital Partners which will be used to strengthen its commercial resources and infrastructure development, aiding cell therapy customers.

Accellix offers a suite of quick and high-accuracy flow cytometry results via easy-to-use and compact platform notably designed for cell therapy company users on the manufacturing floor as well as at the point-of-need customers.

Imperative to note, BroadOak has a broad expertise in flexible growth capital coupled with M&A advice catering to life sciences tools and services companies.

BroadOak’s recent investment in Accellix is apparently a part of the former’s fifth fund and underpins its third investment within last six months in the constantly growing tools and services market for cell and gene therapy development and manufacturing.

Following the initial investment in the biotech company, BroadOak noticed successful execution by Accellix in market-leading products development, stated Bill Snider, Partner at BroadOak Capital Partners.

Adding to the statement, Mr. Snider quoted that BroadOak looks forward to strengthening the partnership as Accellix emerges as the gold standard for cell therapy companies in cell phenotyping.

Nir Nimrodi, Chairman and CEO of Accellix, mentioned that the investment builds upon the company’s plans to propel commercial and development efforts.

Mr. Nimrodi claims that Accellix has acquired 10 times larger customer base in last 2 years, wherein some have already incorporated their commercial GMP manufacturing processes with Accellix Platform.

Meanwhile, Accellix will continue with infrastructure focused investments in order to support customer needs.

Highly potent cell therapies progressing towards late stage clinical development as well as commercial products are fueling the need for a streamlined and continuous quality-control process management.

Accellix addresses the exact need providing products that streamline complex yet vital part of cell analysis, offering more reliable and solid outcomes with reduced QC costs in cell therapy manufacturing.

Source Credits: https://www.businesswire.com/news/home/20211213005247/en/Accellix-Raises-10-Million-From-BroadOak-Capital-Partners

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Covid-19 could end in Europe after the Omicron wave, says WHO
Covid-19 could end in Europe after the Omicron wave, says WHO
By Pankaj Singh

The new Omicron variant has shifted the pandemic into a new phase and could end in Europe, claims WHO Europe Director Hans Kluge recently. Mr. Kluge told sources that it could be possible that the region is heading towards a pandemic endgame, adding...

Scotland scientists develop AI-based test using X-rays to detect COVID-19
Scotland scientists develop AI-based test using X-rays to detect COVID-19
By Pankaj Singh

Scientists in Scotland have reportedly created an AI (artificial intelligence) based test that detects COVID-19,accurately, using X-rays in just a few minutes. The testing platform, developed at the University of the West of Scotland (UWS), can detec...

STG announces launch of Trellix; aims for technological innovation
STG announces launch of Trellix; aims for technological innovation
By Pankaj Singh

Symphony Technology Group (STG), an American private equity firm, has recently announced the launch of Trellix. This innovative business will be bringing prolonged XDR (detection and response) to firms while focusing on fastening technology innovatio...